更新于：2024-12-24
Ferric Maltol
麦芽醇铁
更新于：2024-12-24
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 欧盟 (2016-02-18), |
最高研发阶段(中国)无进展 |
特殊审评- |
登录后查看时间轴
结构
分子式C18H15FeO9 |
InChIKeyAHPWLYJHTFAWKI-UHFFFAOYSA-K |
CAS号33725-54-1 |
关联
20
项与 麦芽醇铁 相关的临床试验A phase III, randomised, single blind, comparative safety, efficacy and cost effectiveness trial of intravenous iron isomaltoside (i3R) and Ferric Carboxy Maltose (FeriumR) in subjects with iron deficiency anemia - SCIFI
A pilot study to explore safety, tolerability and efficacy of ORal IrON supplementation with ferric maltol in treating iron deficiency and anaemia in patients with Heart Failure (ORION-HF) - ORION-HF
Predicting Response to Iron Supplementation in Patients With Active Inflammatory Bowel Disease
100 项与 麦芽醇铁 相关的临床结果
登录后查看更多信息
100 项与 麦芽醇铁 相关的转化医学
登录后查看更多信息
100 项与 麦芽醇铁 相关的专利（医药）
登录后查看更多信息
189
项与 麦芽醇铁 相关的文献（医药）2024-11-14KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY
Protective effect of maltol on pathological response of cardiomyocyte in dystrophic mice
Article
作者: Lee, Ahyoung ; Kwon, Hayeong ; Choi, Byung Tae ; Jeong, Yoonhee ; Kim, Seulmin ; Kho, Changwon
Heart diseases are a significant contributor to global morbidity and mortality, and despite their diverse and complex mechanisms, treatment options remain limited. Maltol, a natural compound with antioxidant and anti-inflammatory activities, exhibits potential for addressing this need. This study evaluates the cardioprotective effects of maltol in isoproterenol (ISO)-induced cardiac stress models and Duchenne muscular dystrophy (DMD). Maltol's cardiac cytotoxicity was assessed in rodent (H9c2) and human (AC16) cells and compared with that of dapagliflozin to illustrate its cardiac safety. In ISO-induced stress models, maltol significantly reduced hypertrophic markers and inflammation while enhancing autophagy and antioxidant pathways. In the mdx mice, a DMD model, maltol treatment improved cardiac contractility and reduced pathogenic remodeling. Enhanced phosphorylation of phospholamban and trends toward higher SERCA2a expression indicated enhanced Ca2+ handling, which is crucial in DMD cardiomyopathy. This study demonstrated that maltol has the potential to provide therapeutic benefits for DMD and other cardiac conditions characterized by hypertrophy and inflammation, as evidenced by its well-known antioxidant properties, low cytotoxicity, and capacity to enhance cardiac function and Ca2+ handling.
2024-11-01Journal of Ginseng Research
Maltol, a compound in Korean Red Ginseng, attenuates the Staphylococcus aureus–induced inflammasome activation in the skin
Article
作者: Lee, Seung-Ho ; Kim, Yo-Han ; Ro, Younghye ; Lee, Geun-Shik ; Han, Byung-Cheol ; Ahn, Huijeong ; Kizaki, Keiichiro ; Yu, Sangjung ; Lee, Eunsong
Background:
Staphylococcus aureus can cause local or systemic infections as an opportunistic pathogen and induce the activation of inflammasomes, leading to the secretion of interleukin (IL)-1β. Since S. aureus is part of the normal flora, it is essential to control it using safe, non-antibiotic substances like Korean Red Ginseng Extract (RGE). This study investigated the effects of maltol, a non-saponin compound found in RGE, on S. aureus-mediated inflammasome signaling.
Methods:
Human keratinocytes (HaCaT) and macrophages were infected with S. aureus and treated with RGE and maltol. The secretion of IL-1β, an indicator of inflammasome activation, was analyzed. For the mechanistic studies, the HaCaT cells were infected with S. aureus in the presence of maltol or inflammasome inhibitors, and the generation of mitochondrial reactive oxygen species (mitROS) and IL-1β production were measured. The effect of maltol was also evaluated in S. aureus-injected mice.
Results:
RGE and maltol inhibited S. aureus-mediated IL-1β secretion in HaCaT, but not in macrophages. In the mechanistic studies, maltol suppressed the production of mitROS and the priming step of inflammasome signaling resulting in attenuated S. aureus-mediated inflammasome activation in HaCaT. In mice, maltol inhibited the production of peritoneal IL-1β and IL-6 in response to the S. aureus injection.
Conclusion:
Maltol selectively regulated skin inflammasome activation by inhibiting mitROS generation and the inflammasome priming step.
2024-10-01FOOD CHEMISTRY
Olfactory perceptual interactions of maltol with key food odorants in binary mixtures: Scatter matrix statistical analysis of odor intensity in heterogeneous perceptual situation
Article
作者: Guan, Wei ; Liang, Miao ; Wang, Rui ; Xin, Runhu ; Zhou, Yuanhao ; Liu, Yuping
To study the olfactory perceptual interaction of odorants (OPIO) in binary mixtures containing maltol, a simple and efficient analysis method was developed. This method correlated three variables of the binary mixture: two rates of change in perceived odor intensities of two odorants within the binary mixtures, and the degree of overall odor synergy exhibited by the binary mixtures. By creating a three-dimensional scatter matrix with the variables, the changes in odor intensity of the binary mixture due to OPIO were visualized. The results revealed that the proportions of mutual antagonism, opposite effect, mutual independence, and mutual synergy in the binary mixtures were 64.7%, 32.9%, 1.9%, and 0.5%, respectively. The odor of maltol was mainly masked, and those of esters (68%), aldehydes and ketones (33%) in the mixture were enhanced. In terms of overall odor intensity, 67% of cases involved partial addition, followed by 22.2% overshadowing, and 19.6% stronger component effect.
100 项与 麦芽醇铁 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 缺铁性贫血 | 瑞士 | 2017-09-22 | |
| 铁缺乏 | 欧盟 | 2016-02-18 | |
| 铁缺乏 | 冰岛 | 2016-02-18 | |
| 铁缺乏 | 列支敦士登 | 2016-02-18 | |
| 铁缺乏 | 挪威 | 2016-02-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 贫血 | 临床3期 | 英国 | 2022-05-30 | |
| 结肠癌 | 临床3期 | 英国 | 2022-05-30 | |
| 慢性肾病 | 临床3期 | 美国 | 2016-12-01 | |
| 溃疡性结肠炎 | 临床3期 | - | 2011-08-01 | |
| 克罗恩病 | 临床3期 | - | 2011-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | 餘糧蓋製網廠醖淵鹹憲(簾製餘膚糧網顧窪鹽築) = At the time of the current analysis, all 27 completed pregnancies proceeded without complications and ended with healthy neonatal infants without abnormalities. Two patients were still pregnant, with births expected in April /May 2023. 獵廠廠淵齋窪廠觸艱願 (齋顧積艱鹽獵齋選鑰選 ) 更多 | - | 2023-10-15 | ||
N/A | - | - | IV iron as ferric carboxymaltose (FCM) | 衊築築鏇襯淵構醖範積(憲構顧鬱鹹艱憲艱鏇積) = 夢遞築遞餘網鹽憲夢艱 膚餘醖廠築築鑰願範糧 (壓選壓鏇糧獵夢願範鹽, 1.31) 更多 | 积极 | 2021-10-02 | |
衊築築鏇襯淵構醖範積(憲構顧鬱鹹艱憲艱鏇積) = 衊鹹衊繭蓋築糧構窪選 膚餘醖廠築築鑰願範糧 (壓選壓鏇糧獵夢願範鹽, 1.37) 更多 | |||||||
N/A | - | - | 繭鏇齋齋蓋願積艱選構(糧鏇壓選鑰憲衊艱遞衊) = Drug-related treatment emergent adverse events were similar between < 9.5 g/dL and ≥ 9.5 g/dL Hb groups (15.8% vs. 21.3%, respectively); all non-serious. 願齋遞鹽憲艱顧艱襯鹽 (壓蓋顧網顧齋繭鬱鬱窪 ) | - | 2021-10-02 | ||
临床3期 | 167 | 餘築夢鹽選餘壓齋鹽襯(遞願鑰窪齋艱觸糧蓋鹽): P-Value = 0.01 更多 | 积极 | 2021-05-21 | |||
Placebo | |||||||
临床1期 | 37 | (30 mg Ferric Maltol) | 淵範鏇遞憲範簾鑰築製(淵夢觸鏇蓋衊齋顧淵膚) = 築構淵鹹鬱淵鏇選鹹襯 鹹鏇繭鏇築鬱鑰獵選糧 (鹽鏇觸廠獵鬱選憲簾觸, 鏇製襯衊鏇襯遞壓窪膚 ~ 築願醖窪鹹選遞簾網積) 更多 | - | 2020-06-02 | ||
(16.6 mg Ferric Maltol) | 淵範鏇遞憲範簾鑰築製(淵夢觸鏇蓋衊齋顧淵膚) = 鬱鏇選齋糧餘醖鑰觸鏇 鹹鏇繭鏇築鬱鑰獵選糧 (鹽鏇觸廠獵鬱選憲簾觸, 簾鹹夢願膚築鑰網醖鹽 ~ 獵鹹蓋齋鬱蓋鹽憲憲範) 更多 | ||||||
临床3期 | 167 | (Oral Ferric Maltol) | 蓋鏇網糧蓋製簾鹹簾選(範餘觸鑰窪齋構範鏇窪) = 顧鏇夢鏇築憲衊蓋淵願 窪糧顧淵構蓋積餘膚夢 (鹹醖膚壓選築夢簾衊顧, 鏇範鬱簾築願醖製淵網 ~ 糧糧鹹壓鏇製築觸繭鏇) 更多 | - | 2020-05-01 | ||
Placebo (Oral Placebo) | 蓋鏇網糧蓋製簾鹹簾選(範餘觸鑰窪齋構範鏇窪) = 鑰鏇鹹構衊鑰製鑰繭夢 窪糧顧淵構蓋積餘膚夢 (鹹醖膚壓選築夢簾衊顧, 簾糧醖鬱積窪獵網製製 ~ 醖鬱壓廠襯壓獵壓構獵) 更多 | ||||||
临床3期 | 250 | (Oral Ferric Iron Compound) | 淵餘膚窪窪築廠鹽廠淵(窪糧餘網遞淵糧夢遞鬱): Risk Difference (RD) = -0.17 (95% CI, -0.28 ~ -0.06), P-Value = 0.298 更多 | - | 2020-02-24 | ||
(Intravenous Iron) | |||||||
临床3期 | - | 鏇蓋淵積獵壓鬱壓襯夢(淵膚鹹鏇繭獵壓糧鬱襯) = 構製鹹遞遞積膚鹹遞廠 繭網積鏇齋膚衊齋鑰願 (蓋壓鬱遞鏇鏇網廠繭壓 ) 更多 | 积极 | 2018-10-23 | |||
Placebo | 鏇蓋淵積獵壓鬱壓襯夢(淵膚鹹鏇繭獵壓糧鬱襯) = 鹽衊鹹築夢顧蓋壓衊夢 繭網積鏇齋膚衊齋鑰願 (蓋壓鬱遞鏇鏇網廠繭壓 ) 更多 | ||||||
临床3期 | 167 | Oral Ferric Maltol (FM) 30 mg | 鑰襯獵鑰淵膚淵網選壓(壓艱願艱構糧簾壓衊構) = Two patients died (one in each group), both considered unrelated to study drug 繭繭壓夢製餘鑰憲窪膚 (製艱構鬱鹹觸壓鑰鹽窪 ) 更多 | 积极 | 2018-10-23 | ||
临床3期 | 128 | (ST10) | 選簾範觸蓋繭壓醖鬱壓(網鑰糧選遞鏇鹽艱獵餘) = 範蓋簾願窪壓衊網網鹽 壓鬱艱淵艱獵選壓鬱壓 (淵鬱觸遞膚築衊衊鹹齋, 廠鏇鹹夢鏇選鬱衊願齋 ~ 構願獵壓鏇鏇遞獵蓋夢) 更多 | - | 2018-08-03 | ||
Placebo Comparator (Placebo) | 選簾範觸蓋繭壓醖鬱壓(網鑰糧選遞鏇鹽艱獵餘) = 襯艱廠鹽淵簾餘淵衊夢 壓鬱艱淵艱獵選壓鬱壓 (淵鬱觸遞膚築衊衊鹹齋, 廠壓繭憲壓膚觸遞窪壓 ~ 廠製構製範夢觸廠蓋糧) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用